Trial Condition(s):

Coronary artery disease

Coronary vasomotor response after Riociguat Exposure (CORONARIES)

Bayer Identifier:

14550

ClinicalTrials.gov Identifier:

NCT01165931

EudraCT Number:

Not Available

Terminated/Withdrawn

Trial Purpose

The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease.

Inclusion Criteria
- Male and female patients with coronary artery disease
Exclusion Criteria
- Patents with coronary artery disease with >/= 70% luminal stenosis by coronary angiography in one of the 3 major epicardial coronary arteries (left anterior descending artery [LAD], left circumflex coronary artery [LCX] or right coronary artery [RCA]) undergoing cardiac catheterization

Trial Summary

Enrollment Goal
0
Trial Dates
black-arrow
Phase
2
Could I receive a placebo?
No
Products
Adempas (Riociguat, BAY63-2521)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Boston, United States, 02114

Status
Terminated
 

Trial Design